ClinicalTrials.gg
RecruitingNCT07737795Updated Nov 18, 2026

Evaluating the Addition of OK-1 Weekly Paclitaxel in Patients With Endometrial Cancer

A Phase 2 interventional study of OK-1 & Paclitaxel in Endometrial Cancer, sponsored by University of Oklahoma. Recruiting at 1 site in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by University of Oklahoma · Phase 2, Interventional, and Treatment

How we know

Updated Nov 18, 2026Now RecruitingSite recruiting status changed+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
66
Allocation
Not applicable
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 39 studies testing paclitaxel in Endometrial Neoplasms — 8 open to participants now, 14 under way, 3 of them phase 3. Paclitaxel · Endometrial Neoplasms.

Planned enrollment
12th of 34
66 · median 42
Started
2026
with 1 other
Phase 2
26 of 39
5 open now
Primary completion
2028-11
later than 10 of 13 live
Registered
38th of 39
by date
Lead sponsor
2 of 39
University of Oklahoma

Among the 39 studies testing paclitaxel in Endometrial Neoplasms, this one is the 12th largest by planned enrollment of the 34 interventional ones that give a count, is one of 2 that started in 2026, is one of 26 in phase 2, reaches primary completion later than 10 of the 13 other live ones, and was the 38th registered.

Endometrial Neoplasms

1,429 studies on the registry are indexed under Endometrial Neoplasms; 470 are open to participants now.

Browse Endometrial Neoplasms studies →

Open to participants now

8 of the 39 studies testing paclitaxel in Endometrial Neoplasms are open now, in 3 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About paclitaxel

Paclitaxel: first FDA approval 1992 (TAXOL), first EMA approval 1999. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 356 Endometrial Neoplasms studies recruiting now, 266 (75%) set no upper age limit and 54 (15%) stop at 75 or younger; 26 take children under 18; 23 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 39 studies testing paclitaxel in Endometrial Neoplasms, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate whether treatment with the investigational drug OK-1 in combination with paclitaxel can reduce tumor burden in patients with advanced or recurrent endometrial cancer (A/R-EC).

Read the detailed description

Participants will receive OK-1 capsules by mouth twice daily in continuous 21-day treatment cycles. Paclitaxel will be administered by intravenous (IV) infusion once weekly during each 21-day cycle. A combined total of 66 patients will participate in this study, with the initial safety lead-in cohort involving 30 patients, followed by 36 new patients enrolled in the phase 2 arm.

Treatment cycles will continue until the participant, the treating physician, or the study team determines that continued participation is no longer appropriate due to disease progression, unacceptable side effects, withdrawal of consent, or another clinical reason. Throughout the study, participants will undergo regular laboratory testing and clinical examinations to monitor their health and treatment response. Participation in the study is expected to last for up to one year.

03

Conditions studied

  • Endometrial Cancer

Keywords

  • OK-1
  • A/R-EC
  • ShetA2
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • At least 18 years-of-age at the time of signature of the form (ICF).
  • documented carcinoma of the endometrium, including endometrioid, serous, mixed adenocarcinoma, clear-cell carcinoma, or carcinosarcoma. Evidence that the endometrial cancer is advanced, recurrent, or persistent and has , or is refractory to curative therapy or established treatments.
  • Must have pre-treatment .
  • by v1.1 is required for the phase 2 portion of the study. Patients with accessible disease are eligible for the safety lead in cohorts. Patients with biochemical recurrent disease only (ie Ca125 elevation or ctDNA elevation in absence of visible disease on CT scan are NOT eligible)
  • (ECOG) performance status of 0 to 2.
  • Patients with a prior or concurrent whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the regimen are eligible for this trial.
  • Adequate organ function, defined in study protocol.
  • Prior therapy: Patients must have received ≥1 platinum-based therapy in the recurrent/ setting and not more than 5 .

    • therapy given for early stage, high risk endometrial cancer does NOT count as the line of qualifying platinum based chemotherapy unless disease recurrence is documented \< 12 months from completion. If >12 months has elapsed, patients should receive another line of platinum based chemotherapy.
    • Maintenance therapy (e.g., bevacizumab, poly adenosine diphosphate-ribose polymerase [PARP] inhibitor, endocrine therapy or will be considered part of the preceding line of therapy.
    • Therapy changed due to toxicity in the absence of progression will be considered part of the same line (i.e., not counted independently)
    • Hormonal therapy will not be counted as a separate line of therapy.
    • Patients should have received an immune checkpoint inhibitor as part of a prior line of therapy unless to participate in this trial.
    • If the Patient has a tumor that is 3+, trastuzumab deruxtecan should have been used unless ineligible.
    • During the course of this clinical trial, if an antibody drug conjugate becomes available therapy for recurrent endometrial cancer, patients should be treated with that therapy unless ineligible
  • The patient must provide study-specific informed consent prior to study entry and, for patients treated in the U.S., authorization permitting release of personal health information.
  • \< 470 msec

Exclusion criteria

Exclusion Criteria:

  • Patients who have received prior weekly paclitaxel for recurrent endometrial cancer.
  • Major surgical procedure within 28 days prior to registration, or anticipation of need for major surgical procedure during the study. Note: Placement of a vascular access device, thoracentesis, and/or paracentesis will not be considered major surgery.
  • Women who are pregnant or are unwilling to discontinue nursing.
  • Evidence of bleeding diathesis or coagulopathy within the past 3 months. Patients are not excluded for past or current use of anticoagulation.
  • There is no prespecified washout from prior therapies.
  • Patients with adverse events related to prior therapies must have resolution to \< grade 1. Patients with ≤ Grade 2 neuropathy or ≤ Grade 2 alopecia are an exception to this criterion and may qualify for the study. Note: Grade 2 neuropathy is neuropathy on one medication so patients may be eligible following discussions with the medical monitor.

Additional exceptions include immune-related AEs such as adrenal insufficiency, hypothyroidism (controlled), endocrine-related toxicities due to treatment (can be corrected through hormone replacement therapy) and Grade 2 laboratory abnormalities that meet the eligibility requirements.

  • Patients currently taking and unwilling/unable to discontinue the use of drugs that are known to be strong/moderate inhibitors or inducers of , CYP2C8, CYP2C19, and CYP2C9. (Refer to Appendix III)
  • Comorbid Conditions: No active infection requiring parental antibiotics except for urinary tract infection.
  • No evidence of intra-abdominal abscess, abdominal/pelvic fistula, gastrointestinal perforation, or GI obstruction requiring gastrostomy tube. NOTE: required interval since last bowel obstruction: 30-day minimum for incomplete obstruction, resolved with conservative means; 6 months for fistula. Patients with a history of a large bowel obstruction that has been successfully diverted and do not meet the criteria for small bowel obstruction are eligible.
  • Patients with risk factors for torsade de pointes (TdP) such as clinically significant heart failure (defined as a known \< 50%), uncorrected grade 2 or greater hypokalemia, family history of long syndrome )
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
66 participants (estimated)

Study arms

  • Experimental
    Phase 2 Cohort

    OK-1 (oral, BID) 28-days cycle. Weekly Paclitaxel (IV) 21-days cycle.

    Drug: OK-1 & Paclitaxel

Interventions

  • DrugPaclitaxelStudies of PaclitaxelPaclitaxel pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    OK-1 capsules will be administered orally at 3.5-4.5 mg/kg twice a day during a 21-day cycle (3 weeks on, one week off in a 28-day cycle) Other Names: • NSC 726189 Paclitaxel will be administered 60-70 mg/m2 IV on Day 1,8 and 15 (3 weeks on, one week off in a 28-day cycle)

06

What researchers measure

Primary outcomes

  1. Number and Proportion of Patients Who Safely Tolerate The Combination of OK-1 and Paclitaxel

    Quantitative assessment of patients who experienced \>gr.3 AEs during OK-1 in combination with a weekly paclitaxel regimen using CTCAE v6

    Time frame: 12 Months

  2. Proportion of Patients Who Successfully Completed The Safety Lead-In Phase and Tolerated OK-1 In Combination With Paclitaxel.

    Completion of safety lead-in with an established phase 2 dose for OK-1 combination with weekly intravenous paclitaxel

    Time frame: 1 Year

  3. Proportion of Participants Overrall Response Rate To OK-1 In Comination With Paclitaxel

    To quantitatively evaluate the overall response rate (ORR) in the Phase 2 cohort by determining the proportion of participants who achieve a complete response (CR) or partial response (PR) to treatment.

    Time frame: 2 Years

Secondary outcomes

  1. Participants Duration of Response To OK-1 In Combination With Paclitaxel

    Assess the number of days from the onset of treatment-induced response to the subsequent progression of the disease or death, or last time of follow-up

    Time frame: 2 years

  2. Assess Progression Free Survival In Participants Who Tolerated OK-1 In Combination With Paclitaxel

    Determine the number of days from the start of study treatment to date of imaging-confirmed study progression, death, or last time of follow-up

    Time frame: 2 years

  3. Overall Survival at 12 Months

    Assess the percentage of patients alive at 12 months post-enrollment.

    Time frame: 2 Years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Nov 2028, 24 months later.

Of 109 non-industry phase 2 interventional studies under Endometrial Neoplasms, half reached primary completion within 60 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 115. This study's planned 24 months is below that.

Counting every sponsor, half of 141 studies reached it within 55 months; a quarter within 37 and three quarters within 115.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 18, 2026: start Aug 2026 → Nov 2026, primary completion Aug 2028 → Nov 2028 and completion Aug 2029 → Nov 2029.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 27, 2026
First posted
Jul 30, 2026
StartEst.
Nov 2026was Aug 2026
Primary completionEst.
Nov 2028was Aug 2028
CompletionEst.
Nov 2029was Aug 2029
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 18, 2026
Sites
OU Health Stephenson Cancer Center is now Recruiting
Nov 18, 2026
Start date
Aug 2026→Nov 2026
Nov 18, 2026
Primary completion
Aug 2028→Nov 2028
Nov 18, 2026
Study completion
Aug 2029→Nov 2029
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    Not yet recruiting→Recruiting
    OU Health Stephenson Cancer Center is now Recruiting
    Start date Aug 2026→Nov 2026
    Primary completion Aug 2028→Nov 2028
    Study completion Aug 2029→Nov 2029
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07737795
Responsible party
Sponsor
First posted
Jul 30, 2026
Start date
Nov 2026 (estimated)
Primary completion
Nov 2028 (estimated)
Completion
Nov 2029 (estimated)
Last update
Nov 18, 2026

Study contacts

Lead Gynecology Oncology Nurse
Contact
SCC-IIT-Office@ouhsc.edu
572-244-0111
Kathleen Moore, MD
principal investigator · Nebraska Medical Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Paclitaxel

Start the discussion